Literature DB >> 10565938

Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences.

N Yahi1, C Tamalet, C Tourrès, N Tivoli, F Ariasi, F Volot, J A Gastaut, H Gallais, J Moreau, J Fantini.   

Abstract

The aim of the present study was to evaluate the resistance-associated mutations in 302 human immunodeficiency virus type 1 (HIV-1)-infected patients receiving combination therapy and monitored in Marseille, France, hospitals from January 1997 to June 1998. In the reverse transcriptase (RT) gene, the most frequent mutations were found at codons 215 (53%), 41 (34%), and 67, 70, 184, and 210 (>20%). One deletion and two insertions in the beta3-beta4 hairpin loop of the finger subdomain (codon 69) were detected. Interesting associations and/or exclusions of specific mutations were observed. In 96% of RT genes, a mutation at codon 70 (most frequently, K70R) was associated with a wild-type genotype at position 210 (P < 10(-5)). Similarly, a mutation at codon 210 (most frequently, L210W) was generally associated with mutations at codons 41 (92%) and 215 (96%) but not at codon 219 (16%) or codon 70 (4%) (P < 10(-5)). In the protease gene, the most prevalent mutations were at codons 63 (84%), followed by codons 10, 36, 71, 77, and 93 (ca. 20%). As for RT, pairwise associations of mutations were observed. Analysis of the mutation patterns for patients with undetectable HIV-1 loads revealed a high proportion (65%) of wild-type RT genotypes but only 18% wild-type protease genotypes. For patients with high viral loads (>100,000 copies/ml), more than 50% of the RT and protease genes displayed three or more mutations. The significant correlation between the level of viremia in plasma and the number of resistance mutations in the protease (P = 0.007) and RT (P = 0.00078) genes strengthens the importance of defining the genotype of the predominant HIV-1 quasispecies before initiating antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10565938      PMCID: PMC85889     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  28 in total

1.  Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

Authors:  C A Boucher; E O'Sullivan; J W Mulder; C Ramautarsing; P Kellam; G Darby; J M Lange; J Goudsmit; B A Larder
Journal:  J Infect Dis       Date:  1992-01       Impact factor: 5.226

2.  Role of methionine 184 of human immunodeficiency virus type-1 reverse transcriptase in the polymerase function and fidelity of DNA synthesis.

Authors:  V N Pandey; N Kaushik; N Rege; S G Sarafianos; P N Yadav; M J Modak
Journal:  Biochemistry       Date:  1996-02-20       Impact factor: 3.162

Review 3.  Retrovirus variation and reverse transcription: abnormal strand transfers result in retrovirus genetic variation.

Authors:  H M Temin
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

4.  Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations.

Authors:  A Meyerhans; R Cheynier; J Albert; M Seth; S Kwok; J Sninsky; L Morfeldt-Månson; B Asjö; S Wain-Hobson
Journal:  Cell       Date:  1989-09-08       Impact factor: 41.582

5.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.

Authors:  J M Coffin
Journal:  Science       Date:  1995-01-27       Impact factor: 47.728

6.  Analysis of heterogeneous viral populations by direct DNA sequencing.

Authors:  T Leitner; E Halapi; G Scarlatti; P Rossi; J Albert; E M Fenyö; M Uhlén
Journal:  Biotechniques       Date:  1993-07       Impact factor: 1.993

7.  Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1.

Authors:  M Hsu; P Inouye; L Rezende; N Richard; Z Li; V R Prasad; M A Wainberg
Journal:  Nucleic Acids Res       Date:  1997-11-15       Impact factor: 16.971

8.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA.

Authors:  A Jacobo-Molina; J Ding; R G Nanni; A D Clark; X Lu; C Tantillo; R L Williams; G Kamer; A L Ferris; P Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

9.  Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy.

Authors:  I Nájera; A Holguín; M E Quiñones-Mateu; M A Muñoz-Fernández; R Nájera; C López-Galíndez; E Domingo
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

Review 10.  Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.

Authors:  C Tantillo; J Ding; A Jacobo-Molina; R G Nanni; P L Boyer; S H Hughes; R Pauwels; K Andries; P A Janssen; E Arnold
Journal:  J Mol Biol       Date:  1994-10-28       Impact factor: 5.469

View more
  33 in total

1.  Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy.

Authors:  E Quiros-Roldan; S Signorini; F Castelli; C Torti; A Patroni; M Airoldi; G Carosi
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

2.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

Review 3.  Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.

Authors:  Mark A Winters; Thomas C Merigan
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

4.  The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.

Authors:  Robert W Shafer; Rami Kantor; Matthew J Gonzales
Journal:  AIDS Rev       Date:  2000       Impact factor: 2.500

5.  Replicative capacity differences of thymidine analog resistance mutations in subtype B and C human immunodeficiency virus type 1.

Authors:  Kimberly L Armstrong; Tun-Hou Lee; M Essex
Journal:  J Virol       Date:  2009-02-18       Impact factor: 5.103

Review 6.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

7.  In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.

Authors:  Zhufang Li; Brian Terry; William Olds; Tricia Protack; Carol Deminie; Beatrice Minassian; Beata Nowicka-Sans; Yongnian Sun; Ira Dicker; Carey Hwang; Max Lataillade; George J Hanna; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

8.  Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance.

Authors:  Galina N Nikolenko; Krista A Delviks-Frankenberry; Sarah Palmer; Frank Maldarelli; Matthew J Fivash; John M Coffin; Vinay K Pathak
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-19       Impact factor: 11.205

9.  The "Connection" Between HIV Drug Resistance and RNase H.

Authors:  Krista A Delviks-Frankenberry; Galina N Nikolenko; Vinay K Pathak
Journal:  Viruses       Date:  2010-07-01       Impact factor: 5.048

10.  Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.

Authors:  Sarah K Ho; Elena E Perez; Stephanie L Rose; Roxana M Coman; Amanda C Lowe; Wei Hou; Changxing Ma; Robert M Lawrence; Ben M Dunn; John W Sleasman; Maureen M Goodenow
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.